Management ChangeMay 29, 2026, 05:07 PM
Scienture Holdings Appoints Dr. Narasimhan Mani as Interim CFO
AI Summary
Scienture Holdings, Inc. announced the resignation of Eric Sherb as Chief Financial Officer, effective May 26, 2026, due to personal reasons and not any dispute with the company. Concurrently, Dr. Narasimhan Mani, currently Co-Chief Executive Officer and President, was appointed Interim CFO. Dr. Mani brings over 25 years of experience in the pharmaceutical industry, including senior management and financial operations roles, and holds an MBA in Finance and Marketing.
Key Highlights
- Eric Sherb resigned as Chief Financial Officer of Scienture Holdings, Inc. on May 26, 2026, citing personal reasons.
- Dr. Narasimhan Mani was appointed Interim Chief Financial Officer, effective May 26, 2026.
- Dr. Mani has served as a director, Co-Chief Executive Officer, and President of the Company since May 2025.
- He possesses over 25 years of experience in the pharmaceutical industry, including senior management and financial roles.
- Dr. Mani holds an MBA in Finance and Marketing from Columbia Business School and a Ph.D. in Pharmaceutics.
Price Impact
More from SCNX